Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. A.J. van der Wekken

Publicaties

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer

Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients

Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Pers/media

Door chemotekorten worden minder effectieve behandelingen ingezet

Stand van Nederland - Wereld op Scherp: Een bittere pil (WNL NPO2)

RTV Noord Vandaag

Effect van pil tegen longkanker

Pil tegen longkanker 'halveert kans op overlijden' voor kleine groep patiënten

Hoop voor kleine groep longkankerpatiënten: pil per dag halveert kans op overlijden

Doelgerichte therapie bij longkanker

Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Longkanker: welke vorm heb ik?